Prevenar 13®* Receives CHMP Positive Opinion For Prevention Of Vaccine-Type Pneumococcal Pneumonia in Adults
January 22, 2015 11:21 AM Eastern Standard Time
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the European Medicines Agency's Committee for Medicinal Products for...
Specialty Vaccine Company PaxVax Appoints Nima Farzan as President
REDWOOD CITY, Calif. – January 21, 2015 – PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced the appointment of Nima Farzan as President and...
Health Canada Clears Immunovaccine to Conduct Phase I Clinical Trial of Respiratory Syncytial Virus (RSV) Vaccine
First Clinical Study in Infectious Disease Indication with a DepoVax(TM)-Based Vaccine
HALIFAX, NOVA SCOTIA, Jan 20, 2015 (Marketwired via COMTEX) -- Immunovaccine Inc....
Aduro Biotech Reports Long-term Survival and Immune Biomarker Data From Phase 2 Clinical Trial of Its Immuno-oncology Regimen in Patients With Pancreatic Cancer
BERKELEY, Calif.--(Business Wire)--Aduro Biotech, Inc. today announced that seven pancreatic cancer patients treated with its combination immuno-oncology regimen in a 93-patient Phase 2a clinical...
Johnson & Johnson Announces Formation of Ebola Vaccine Development Consortia, Gains Funding from Innovative Medicines Initiative
NEW BRUNSWICK, N.J., Jan. 16, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) is pleased to announce the formation of consortia with leading global research institutions and non-government...
GSK GLOBAL VACCINES CHAIRMAN MONCEF SLAOUI JOINS IAVI BOARD OF DIRECTORS
The International AIDS Vaccine Initiative (IAVI) is pleased to announce that Dr. Moncef Slaoui, Chairman, Global Vaccines, GlaxoSmithKline (GSK), has joined its Board of Directors.
"Moncef...
Aduro Biotech Announces Phase 2 Clinical Trial Results for Pancreatic Cancer Combination Immunotherapy Published in Journal of Clinical Oncology
Aduro Biotech Announces Phase 2 Clinical Trial Results for Pancreatic Cancer Combination Immunotherapy Published in Journal of Clinical Oncology
- Statistically Significant Survival Benefit...
WHO grants approval for safe, effective meningitis A vaccine for infants
New technology already has achieved dramatic drop in major cause of deadly epidemics in sub-Saharan Africa GENEVA - 9 JANUARY 2015 - The World Health Organization (WHO) has opened the door to routine...
Johnson & Johnson Announces Start of Phase 1 Clinical Trial of Ebola Vaccine Regimen
NEW BRUNSWICK, N.J., Jan. 6, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the start of a Phase 1, first-in-human clinical trial of a preventive Ebola vaccine in development...
Bavarian Nordic Announces Initiation of Phase 1 Clinical Trial for the Ebola Vaccine Regimen of MVA-BN® Filo and Janssen's AdVac® technology
First human trial of the MVA-BN® Filo/AdVac® preventative Ebola vaccine regimen initiated in the UK Additional trials soon to be initiated in United States and Africa Company now expects...
NewLink Genetics, Merck Collaboration to Manufacture Ebola Vaccine Candidate Supported by $30 Million Government Award
NewLink Genetics, Merck Collaboration to Manufacture Ebola Vaccine Candidate Supported by $30 Million Government Award AMES, Iowa and KENILWORTH, N.J., Dec. 22, 2014 (GLOBE NEWSWIRE) -- NewLink...
Seattle Researchers are a Significant Step Closer to an HIV Vaccine
Research team finds a vaccine candidate that stimulates the production of neutralizing antibodies that defend against infection from a broad spectrum of HIV strains SEATTLE--(BUSINESS WIRE)--
A...
ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine
LOS ANGELES, Dec. 17, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced that the US Patent and Trademark Office (USPTO) has issued a key...
Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint
GSK today announced that a pivotal phase III study to assess the efficacy of HZ/su, an investigational vaccine for the prevention of shingles, has met its primary endpoint.
Analysis of the...
Baxter to Divest Vero Cell Vaccines Platform to Nanotherapeutics
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced that it has entered into a definitive agreement to sell its proprietary Vero cell technology and related...
Sanofi Pasteur Announces FDA Approval of Fluzone® Intradermal Quadrivalent (Influenza Vaccine) for Adults
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental biologics license...
Vical Completes Enrollment in Its Therapeutic HSV-2 Vaccine Clinical Trial
SAN DIEGO, Dec. 11, 2014 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the completion of enrollment in a Phase 1/2 trial of its Vaxfectin®-formulated therapeutic vaccine...
FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV
The U.S. Food and Drug Administration today approved Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for the prevention of certain diseases caused by nine types of Human...
Secretary Burwell issues declaration under PREP Act to support development of Ebola vaccines
Important step in effort to develop Ebola vaccines to combat current, future outbreaks Health and Human Services Secretary Sylvia M. Burwell today announced a declaration under the Public Readiness...
VaxInnate Initiates Phase 1b/2 Clinical Trial of Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, in Elderly
Study to assess safety and immunogenicity in high-priority, at-risk population; top-line results expected in second quarter of 2015 Cranbury, NJ, Dec. 8, 2014 (GLOBE NEWSWIRE) -- VaxInnate...
